Triple Negative Breast Cancer Clinical Trials 2024

Triple Negative Breast Cancer Clinical Trials 2024

Triple Negative Breast Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in triple negative breast cancer clinical trials today.

Trials for Breast Cancer Patients

Trials for LABC Patients

Trials for Metastatic Patients

Trials for PD-L1 Positive Patients

Trials for ER Positive Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to triple negative breast cancer

What are the top hospitals conducting triple negative breast cancer research?

When it comes to clinical trials dedicated to tackling the formidable challenge of triple negative breast cancer, several hospitals have emerged as leaders in this field. In Boston, Massachusetts General Hospital is at the forefront with nine active trials focused on triple negative breast cancer and a total of 34 completed studies in this area. Their commitment dates back to 2011 when they initiated their first recorded trial for this specific type of breast cancer. Not far behind, the Dana-Farber Cancer Institute also located in Boston, is making significant strides with eight ongoing clinical trials and an impressive history of 33 previous trials since their inaugural study in 2010 that addressed triple negative breast cancer.

Meanwhile, Memorial Sloan Kettering Cancer Center situated in New york City has established itself as another prominent institution actively engaged in combating triple negative breast cancer. With seven ongoing trials and a remarkable record of 38 completed studies over time since their initial investigation began in 2011 specifically targeting this aggressive form of breast cancer; here too great dedication can be seen towards finding new treatments.

Further down south, MD Anderson Cancer Center based out Houston plays its part by conducting six current clinical tests while having accumulated notable expertise through fourteen previous experiments after launching its first recorded trial centered around triple-negative tumors just a decade ago from now- i.e.,inthe year2012.And finally highlighting Beth Israel Deaconess Medical Center which stands alongside MD Anderson by also contributing six ongoing investigations into developing breakthroughs againsttriple-negativebreastcancer.NotwithstandingbeingrelativelynewerinthefieldtheyalongsidehaveachievedeighteencompletedclinicalstudieswhichstartedwaybacktowardsthoseearlyyearsfromtheirfirsttrialinitiatedinthesimilarlyyearasDanaFarbersonei.e.,during theyearof2010.

With these esteemed institutions leading the charge against triple negative breast cancer through cutting-edge research and innovative clinical trials,tremendoushopeandpotentialforadvancementarebroughttothe table. The collaborative efforts of these top hospitals demonstrate a unified commitment to finding treatments and improving outcomes for those affected by this challenging form of breast cancer.

Which are the best cities for triple negative breast cancer clinical trials?

When it comes to clinical trials for triple negative breast cancer, several cities emerge as top contenders. Boston, Massachusetts leads the pack with 44 active trials investigating Pembrolizumab, Atezolizumab, Cediranib Maleate, and other promising treatments. Houston, Texas closely follows with 40 ongoing studies centered around Pembrolizumab and innovative approaches for tumors larger than 5 cm. New York City also boasts 40 active trials focusing on BMS-986340, Pembrolizumab, Carboplatin, and other potential breakthroughs. Nashville, Tennessee and Chicago, Illinois round out the list with their respective contributions of 33 and 27 active trials exploring Enzalutamide, DF6002,TAK-676,and more. These cities offer hope to individuals battling triple negative breast cancer through cutting-edge research that may lead to improved treatment options in the future.

Which are the top treatments for triple negative breast cancer being explored in clinical trials?

In the realm of clinical trials, several treatments are currently under exploration for triple negative breast cancer. Taking the lead is pembrolizumab, impressively involved in 17 active trials and boasting a total of 82 all-time studies dedicated to this aggressive subtype since its introduction in 2015. Atezolizumab follows closely behind with four ongoing trials and a history of 27 all-time triple negative breast cancer studies since its debut in 2015. Additionally, enzalutamide has shown promise, participating in two active trials and totaling five all-time triple negative breast cancer trials since being listed in 2013. On the horizon are newer contenders NUV-868 and SGN-B7H4V, each making their mark with one active trial and one all-time trial respectively after being introduced just last year (2022). As research progresses tirelessly, these potential breakthroughs offer hope for improved treatment options against this challenging form of breast cancer.

What are the most recent clinical trials for triple negative breast cancer?

Recent clinical trials have brought forth promising advancements in the field of triple negative breast cancer, offering new possibilities for treatment. One notable study focuses on tumors larger than 5 cm and aims to enhance therapeutic outcomes in this specific subgroup. Another trial explores the potential benefits of an Anti-HER2/HER3 Dendritic Cell Vaccine, which holds promise as a targeted approach against triple negative breast cancer. Additionally, researchers are investigating the efficacy and safety profile of SGN-PDL1V and NUV-868 for this aggressive form of breast cancer. These trials mark significant progress in our understanding and management of triple negative breast cancer, providing hope for improved patient outcomes in the future.

What triple negative breast cancer clinical trials were recently completed?

Recent clinical trials have made significant progress in the search for effective treatments for triple negative breast cancer. G1 Therapeutics, Inc.'s trial on Trilaciclib was completed in November 2021, showing promising results. In October 2020, VelosBio Inc. concluded their study on Zilovertamab vedotin, which holds potential as a treatment option. Another notable trial was conducted by Hoffmann-La Roche and focused on Tiragolumab; it reached completion in September 2020. These advancements bring hope to those affected by triple negative breast cancer and highlight the ongoing commitment of researchers to find new breakthroughs that could improve patient outcomes.